Clarius Group LLC Purchases 917 Shares of Cencora, Inc. (NYSE:COR)

Clarius Group LLC boosted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 60.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,426 shares of the company's stock after purchasing an additional 917 shares during the period. Clarius Group LLC's holdings in Cencora were worth $675,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Net Worth Advisory Group increased its position in shares of Cencora by 1.4% during the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after purchasing an additional 36 shares during the period. Whittier Trust Co. increased its position in shares of Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after purchasing an additional 44 shares during the period. JFS Wealth Advisors LLC increased its position in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. Cullen Frost Bankers Inc. increased its position in shares of Cencora by 1.1% during the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after purchasing an additional 47 shares during the period. Finally, Permanent Capital Management LP increased its position in shares of Cencora by 4.0% during the 1st quarter. Permanent Capital Management LP now owns 1,238 shares of the company's stock valued at $344,000 after purchasing an additional 48 shares during the period. Institutional investors own 97.52% of the company's stock.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now directly owns 315,913 shares in the company, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,253 shares of company stock worth $10,582,297. Company insiders own 10.80% of the company's stock.

Cencora Stock Down 1.0%

Shares of NYSE:COR traded down $3.09 on Friday, reaching $293.66. The company had a trading volume of 3,544,162 shares, compared to its average volume of 1,519,935. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The stock has a 50-day moving average price of $288.98 and a 200 day moving average price of $263.29. The stock has a market capitalization of $56.92 billion, a P/E ratio of 34.07, a P/E/G ratio of 1.45 and a beta of 0.58. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.80 earnings per share. On average, equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora's payout ratio is presently 25.52%.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of recent analyst reports. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $274.00 to $337.00 in a research report on Tuesday, June 3rd. UBS Group boosted their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Morgan Stanley set a $288.00 target price on Cencora in a research report on Tuesday, April 15th. Citigroup upped their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $306.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.